Breaking News

ProCell for Patient Project to Develop Automated Production Unit for CAR-T Cell Therapies

Standardized and automated manufacturing aims to reduce the amount of work on producing CAR-T cells by 50 percent.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The Robert-Bosch-Krankenhaus (RBK) in Stuttgart, the Universitätsklinikum Heidelberg and the Pharma Division of the Schwaebisch Hall-based special machine manufacturer Optima launched a project called “ProCell for Patient” that aims to develop a production system for CAR-T cell therapies.   Since 2017, five CAR-T cell products have been approved worldwide: Kymriah (Novartis), Yescarta and Tecartus (Kite/Gilead) and most recently Breyanzi (BMS) and Abecma (bluebird bio & BMS). There a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters